Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
MDM 0.060 +0.0% WGX 4.28 −3.4% FL 0.407 −0.6% SSRM 35.73 −1.7% CD 0.240 +4.3% GEN 0.070 +0.0% ALS 55.93 −2.7% LIFT 3.11 −1.3% NTR 94.11 −0.2% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0% RJX 0.030 +0.0% PRU 4.54 −2.2% MOO 0.720 +0.0% BSX 0.905 −4.7% MDM 0.060 +0.0% WGX 4.28 −3.4% FL 0.407 −0.6% SSRM 35.73 −1.7% CD 0.240 +4.3% GEN 0.070 +0.0% ALS 55.93 −2.7% LIFT 3.11 −1.3% NTR 94.11 −0.2% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0% RJX 0.030 +0.0% PRU 4.54 −2.2% MOO 0.720 +0.0% BSX 0.905 −4.7%

Healthcare

Page 102
  1. Nov 14, 2025 · 17:16 · BETR

    Betterlife director Beaudry resigns; arranges debt deal

    Betterlife director Beaudry resigns; arranges debt deal

    01
  2. Nov 14, 2025 · 17:15 · CSCI

    COSCIENS Biopharma Inc. Announces Leadership Change

    COSCIENS Biopharma Inc. Announces Leadership Change

    02
  3. Nov 14, 2025 · 11:30 · MSCL

    Satellos spends $4M (U.S.) on R&D in Q3 2025

    Satellos spends $4M (U.S.) on R&D in Q3 2025

    03
  4. Nov 14, 2025 · 07:00 · MSCL

    Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors

    Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors

    04
  5. Nov 13, 2025 · 23:11 · FRX

    Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

    Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

    05
  6. Nov 13, 2025 · 20:43 · RX

    BioSyent to release Q3 results Nov. 20

    BioSyent to release Q3 results Nov. 20

    06
  7. Nov 13, 2025 · 18:32 · MBIO

    Mindbio talks initial MB22001 phase 2B trial results

    Mindbio talks initial MB22001 phase 2B trial results

    07
  8. Nov 13, 2025 · 17:43 · MDNA

    Medicenna's fiscal Q2 2026 R&D expenses at $4.1M

    Medicenna's fiscal Q2 2026 R&D expenses at $4.1M

    08
  9. Nov 13, 2025 · 17:40 · CRDL

    Cardiol gains U.S. patent for heart drugs to 2040

    Cardiol gains U.S. patent for heart drugs to 2040

    09
  10. Nov 13, 2025 · 17:30 · MPH

    Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

    Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

    10
  11. Nov 13, 2025 · 17:21 · APLI

    Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

    Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

    11
  12. Nov 13, 2025 · 17:01 · WELL

    Well Health's OceanMD wins e-referral contract

    Well Health's OceanMD wins e-referral contract

    12
  13. Nov 13, 2025 · 17:00 · APS

    Aptose Reports Third Quarter 2025 Results

    Aptose Reports Third Quarter 2025 Results

    13
  14. Nov 13, 2025 · 17:00 · EPRX

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    14
← Newer Older →